- Home
- KALV vs IMNM Comparison
KALV vs IMNM Comparison
Compare KALV & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- IMNM
- Stock Information
- Founded
- KALV N/A
- IMNM 2006
- Country
- KALV United States
- IMNM United States
- Employees
- KALV N/A
- IMNM N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- KALV Health Care
- IMNM Health Care
- Exchange
- KALV Nasdaq
- IMNM Nasdaq
- Market Cap
- KALV 563.1M
- IMNM 542.6M
- IPO Year
- KALV N/A
- IMNM 2020
- Fundamental
- Price
- KALV $12.00
- IMNM $7.91
- Analyst Decision
- KALV Strong Buy
- IMNM Strong Buy
- Analyst Count
- KALV 8
- IMNM 6
- Target Price
- KALV $24.83
- IMNM $26.00
- AVG Volume (30 Days)
- KALV 729.1K
- IMNM 1.7M
- Earning Date
- KALV 03-12-2025
- IMNM 05-13-2025
- Dividend Yield
- KALV N/A
- IMNM N/A
- EPS Growth
- KALV N/A
- IMNM N/A
- EPS
- KALV N/A
- IMNM N/A
- Revenue
- KALV N/A
- IMNM $9,041,000.00
- Revenue This Year
- KALV N/A
- IMNM N/A
- Revenue Next Year
- KALV N/A
- IMNM $1,259.12
- P/E Ratio
- KALV N/A
- IMNM N/A
- Revenue Growth
- KALV N/A
- IMNM N/A
- 52 Week Low
- KALV $7.30
- IMNM $5.15
- 52 Week High
- KALV $15.50
- IMNM $19.07
- Technical
- Relative Strength Index (RSI)
- KALV 55.34
- IMNM 55.28
- Support Level
- KALV $11.42
- IMNM $6.96
- Resistance Level
- KALV $12.35
- IMNM $7.56
- Average True Range (ATR)
- KALV 0.96
- IMNM 0.69
- MACD
- KALV 0.04
- IMNM 0.26
- Stochastic Oscillator
- KALV 88.74
- IMNM 98.22
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.